Skip to main content

TRIUMPH-4 Retatrutide GLP-1 in Osteoarthritis

Dr. Bella Mehta | Abstract 0871 | ACR 2026

Transcription

Hi, this is Bella Meta from ACR 2026 reporting live. I've just come out of the plenary today and I think one of the very important studies in knee osteoarthritis was discussed. This is the TRIUMPH 4 study, which is looking at what I call RETA. Again I'm not great at pronouncing it, but it's RETA, which is a GLP-1 triple agonist — which is GLP-1, GIP, and glucagon. These are the three agonists that it works on.

What we saw is that this was a phase three double-blind placebo-controlled study with three arms: one at 8 milligrams, one at 12 milligrams, and one placebo. This was patients followed over time. And the weight loss in these drugs has become more and more significant — most of the patients lost around 25 to 27% of their body weight.

But most importantly, the primary endpoint was WOMAC pain scores, and at both the dosage intervals it reached the primary endpoint. The pain scores for both the doses seem to go along what was expected, or go along hand in hand. However, the weight loss was much more on the higher dose arm. So I almost think that there's probably some thresholding happening, and at 8 mg subcutaneous weekly dosage patients did as well with the pain as 12 mg.

So with that, I think there are more and more options in knee osteoarthritis, which we've never had for a long time. This was the triple agonist therapy — not triple drug therapy in RA, but triple agonist in OA. It's a single drug. We're already starting to see this data. The placebo responses are also significant in some of these trials, but I think the TRIUMPH trial did show much better outcomes than the STEP 9 trial, for example.

So I loved that there was such significant pain reduction with this drug. Getting some more options in osteoarthritis is amazing. This is one of the big trials at ACR. And with that, signing off — Bella Meta — follow us on RheumNow.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×